J&J/Genmab’s Darzalex Leads Way For Anti-CD38 Antibodies in Myeloma
This article was originally published in The Pink Sheet Daily
Speedy even by the standards of accelerated approval, FDA’s clearance of first-in-class daratumumab in salvage setting gives hope for broader ambitions in myeloma and beyond.
You may also be interested in...
J&J’s Oncology Strategy: Aim For Next-Gen Immuno-Oncology, More M&A
Johnson & Johnson has built a strong oncology business by making smart partnering plays. Now the company is looking to write a new chapter, building on its single-asset successes with a portfolio of new cancer drugs developed both internally and through more M&A.
Janssen Boosts Multiple Myeloma R&D With Genmab Deal
Janssen Biotech has signed its second deal in less than two months with antibody discovery company Genmab, this time licensing the Danish company's potential first-in-class multiple myeloma therapy daratumumab for $55 million upfront and an equity investment.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.